Celldex Therapeutics Inc (NASDAQ: CLDX) is -36.64% lower on its value in year-to-date trading and has touched a low of $22.93 and a high of $53.18 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CLDX stock was last observed hovering at around $24.77 in the last trading session, with the day’s loss setting it -0.11%.
Currently trading at $24.66, the stock is -5.92% and -7.36% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.27 million and changing -0.44% at the moment leaves the stock -29.56% off its SMA200. CLDX registered -36.35% loss for a year compared to 6-month loss of -30.41%. The firm has a 50-day simple moving average (SMA 50) of $26.7226 and a 200-day simple moving average (SMA200) of $35.11585.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -6.99% gain in the last 1 month and extending the period to 3 months gives it a -30.23%, and is -3.49% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.38% over the week and 4.99% over the month.
Celldex Therapeutics Inc (CLDX) has around 160 employees, a market worth around $1.67B and $9.98M in sales. Profit margin for the company is -1544.48%. Distance from 52-week low is 7.55% and -53.63% from its 52-week high. The company has generated returns on investments over the last 12 months (-19.56%).
with sales reaching $1.31M over the same period.The EPS is expected to grow by 15.99% this year, but quarterly earnings will post -0.78% year-over-year. Quarterly sales are estimated to shrink -68.37% in year-over-year returns.
Celldex Therapeutics Inc (CLDX) Top Institutional Holders
259.0 institutions hold shares in Celldex Therapeutics Inc (CLDX), with institutional investors hold 110.55% of the company’s shares. The shares outstanding are 66.34M, and float is at 64.70M with Short Float at 11.90%. Institutions hold 110.22% of the Float.
The top institutional shareholder in the company is WELLINGTON MANAGEMENT GROUP LLP with over 8.08 million shares valued at $298.89 million. The investor’s holdings represent 13.718% of the CLDX Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 7.83 million shares valued at $289.76 million to account for 13.2988 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 4.69 million shares representing 7.9679% and valued at over $173.61 million, while VANGUARD GROUP INC holds 6.3512 of the shares totaling 3.74 million with a market value of $138.38 million.
Celldex Therapeutics Inc (CLDX) Insider Activity
The most recent transaction is an insider purchase by Marucci Anthony S, the company’s PRESIDENT & CEO. SEC filings show that Marucci Anthony S bought 11,500 shares of the company’s common stock on Nov 11 ’24 at a price of $26.82 per share for a total of $0.31 million. Following the purchase, the insider now owns 40284.0 shares.
Celldex Therapeutics Inc disclosed in a document filed with the SEC on Jun 14 ’24 that Martin Samuel Bates (SVP AND CFO) sold a total of 17,172 shares of the company’s common stock. The trade occurred on Jun 14 ’24 and was made at $35.42 per share for $0.61 million. Following the transaction, the insider now directly holds 28125.0 shares of the CLDX stock.
Still, SEC filings show that on Jun 14 ’24, Crowley Elizabeth (SR. VP & CPDO) disposed off 30,000 shares at an average price of $34.87 for $1.05 million. The insider now directly holds 9,074 shares of Celldex Therapeutics Inc (CLDX).
